Mounjaro Online UK

Mounjaro contains tirzepatide. This is a first-in-class medicine that works in two ways at once.

It is a dual receptor agonist, which means it switches on two gut hormone receptors: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1).

You take it as a subcutaneous injection, which means an injection just under the skin. It is licensed to treat type 2 diabetes mellitus.

In some countries it is also licensed for long-term weight management. This applies to adults with obesity, or adults who are overweight and have weight-related health problems.

Tirzepatide acts on both the GIP and GLP-1 receptors. This gives stronger effects than medicines that act on the GLP-1 receptor alone. It helps your body release insulin when blood sugar is high.

It lowers glucagon, a hormone that raises blood sugar, when levels are too high. It slows down how fast your stomach empties. It also reduces appetite, so you eat less.

Acting on both receptors is thought to add up to better blood sugar control and greater weight loss.

The SURPASS and SURMOUNT trials tested tirzepatide. They showed it lowered HbA1c (a measure of average blood sugar) and body weight more than semaglutide 1 mg and more than placebo.

In the SURMOUNT-1 trial, people on the highest dose lost about 22.5% of their body weight over 72 weeks. This makes Mounjaro one of the most effective weight-loss medicines available today.

You give Mounjaro as a subcutaneous injection (an injection just under the skin) once a week. Use it on the same day each week. You can take it at any time of day, with or without food.

Inject it into your abdomen, thigh, or upper arm. Change the injection site each week. The dose is raised slowly over several months until you reach your target dose.

If you miss a dose, check how long it is until your next planned dose. If the next dose is more than four days away, inject the missed dose as soon as you can.

If it is sooner than that, skip the missed dose and go back to your usual weekly schedule.

The starting dose is 2.5 mg once a week for four weeks. Then it goes up to 5 mg once a week. If you need more blood sugar control or weight loss, the dose can rise in steps of 2.5 mg.

Each step is at least four weeks apart. The most you can take is 15 mg once a week. The available strengths are 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.

You do not need to change the dose if you have kidney or liver problems. However, it has not been studied in people with severe liver problems.

Very common (more than 1 in 10): feeling sick (nausea), diarrhoea, less appetite, being sick (vomiting), constipation. These gut-related effects are most common while the dose is going up.

They usually ease over time.

Common (1 in 10 to 1 in 100): tummy pain, indigestion (dyspepsia), acid reflux (gastro-oesophageal reflux), reactions at the injection site, tiredness, low blood sugar (hypoglycaemia, especially with sulfonylureas or insulin), dizziness, hair loss (alopecia), burping (eructation), and wind (flatulence).

Uncommon (1 in 100 to 1 in 1,000): pancreatitis (inflamed pancreas), gallstones (cholelithiasis), inflamed gallbladder (cholecystitis), faster heartbeat, and acute kidney injury caused by becoming dehydrated.

Rare: thyroid C-cell tumours. These were seen in animal studies. It is not clear whether they matter in humans.

Pancreatitis means an inflamed pancreas. It has been reported with incretin-based medicines like this one. Stop Mounjaro if pancreatitis is suspected. Some people should not use tirzepatide.

This applies if you, or your family, have a history of medullary thyroid carcinoma (a type of thyroid cancer). It also applies to multiple endocrine neoplasia syndrome type 2.

Watch for gallbladder problems during fast weight loss. Drink enough fluids. This lowers the risk of dehydration from gut side effects.

If you take insulin or sulfonylureas, you may need a lower dose. This helps prevent low blood sugar (hypoglycaemia). Talk about reliable contraception too.

Weight loss may raise fertility in women with polycystic ovary syndrome.

Do not use Mounjaro if you, or your family, have a history of medullary thyroid carcinoma (a type of thyroid cancer) or multiple endocrine neoplasia syndrome type 2.

Do not use it if you are allergic to tirzepatide or any other ingredient. Do not use it during pregnancy or while breastfeeding. It should not be used in people with type 1 diabetes.